Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease (DHA)

This study has been completed.
Sponsor:
Collaborators:
National Institute on Aging (NIA)
DSM Nutritional Products, Inc.
Information provided by (Responsible Party):
Alzheimer's Disease Cooperative Study (ADCS)
ClinicalTrials.gov Identifier:
NCT00440050
First received: February 22, 2007
Last updated: September 15, 2014
Last verified: September 2014
Results First Received: May 28, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Alzheimer's Disease
Interventions: Drug: DHA (Docosahexaenoic Acid)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited at 51 sites in the United States between February and November 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Out of 555 subjects screened, 402 met the study criteria and were randomized.

Reporting Groups
  Description
Placebo Dosing of 2 grams of placebo administered in a divided dose twice daily with food.
Docosahexaenoic Acid (DHA) Dosing of 2 grams of DHA administered in a divided dose twice daily with food.

Participant Flow:   Overall Study
    Placebo   Docosahexaenoic Acid (DHA)
STARTED   164   238 
COMPLETED   124   171 
NOT COMPLETED   40   67 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Dosing of 2 grams of placebo administered in a divided dose twice daily with food.
Docosahexaenoic Acid (DHA) Dosing of 2 grams of DHA administered in a divided dose twice daily with food.
Total Total of all reporting groups

Baseline Measures
   Placebo   Docosahexaenoic Acid (DHA)   Total 
Overall Participants Analyzed 
[Units: Participants]
 164   238   402 
Age 
[Units: Years]
Mean (Standard Deviation)
 76  (9.3)   76  (7.8)   76  (8.7) 
Gender 
[Units: Participants]
     
Female   98   112   210 
Male   66   126   192 
Region of Enrollment 
[Units: Participants]
     
United States   164   238   402 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Rate of Change on the ADAS-Cog 11.   [ Time Frame: Baseline, 6, 12, 18 months ]
  Hide Outcome Measure 1

Measure Type Primary
Measure Title Rate of Change on the ADAS-Cog 11.
Measure Description ADAS-cog 11 = Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year. This is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment.
Time Frame Baseline, 6, 12, 18 months  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Dosing of 2 grams of placebo administered in a divided dose twice daily with food.
Docosahexaenoic Acid (DHA) Dosing of 2 grams of DHA administered in a divided dose twice daily with food.

Measured Values
   Placebo   Docosahexaenoic Acid (DHA) 
Participants Analyzed 
[Units: Participants]
 164   238 
Rate of Change on the ADAS-Cog 11. 
[Units: ADAS points per year]
Mean (Standard Deviation)
 7.98  (9.84)   8.27  (8.9) 

No statistical analysis provided for Rate of Change on the ADAS-Cog 11.



2.  Primary:   Rate of Change on CDR-SOB   [ Time Frame: 18 months ]

3.  Secondary:   ADCS-ADL   [ Time Frame: 18 months ]
  Hide Outcome Measure 3

Measure Type Secondary
Measure Title ADCS-ADL
Measure Description ADCS-ADL = Alzheimer's Disease Cooperative Study Activities of Daily Living Score. This is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 6 with lower numbers indicating greater impairment.
Time Frame 18 months  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Dosing of 2 grams of placebo administered in a divided dose twice daily with food.
Docosahexaenoic Acid (DHA) Dosing of 2 grams of DHA administered in a divided dose twice daily with food.

Measured Values
   Placebo   Docosahexaenoic Acid (DHA) 
Participants Analyzed 
[Units: Participants]
 164   238 
ADCS-ADL 
[Units: Units on a scale]
Mean (Standard Deviation)
 10.43  (11.74)   11.51  (13.23) 

No statistical analysis provided for ADCS-ADL



4.  Secondary:   Neuropsychiatric Inventory (NPI)   [ Time Frame: 18 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information